NTRK3 and adenoid cystic carcinoma: Molecular characterization plays a growing role in diagnosis and precision therapy, exemplified by the identification of ETV6–NTRK3 fusions in secretory carcinoma and MYB rearrangements in adenoid cystic carcinoma.